KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biolife Solutions (BLFS) Invested Capital (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Invested Capital for 16 consecutive years, with $376.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 3.3% to $376.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $376.9 million, a 3.3% increase, with the full-year FY2025 number at $376.9 million, up 3.3% from a year prior.
  • Invested Capital was $376.9 million for Q4 2025 at Biolife Solutions, up from $361.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $489.7 million in Q3 2021 to a low of $209.2 million in Q1 2021.
  • A 5-year average of $382.0 million and a median of $371.2 million in 2025 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 323.94% in 2021, then fell 23.02% in 2023.
  • Biolife Solutions' Invested Capital stood at $485.3 million in 2021, then fell by 19.67% to $389.8 million in 2022, then fell by 7.26% to $361.5 million in 2023, then increased by 0.92% to $364.8 million in 2024, then rose by 3.3% to $376.9 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Invested Capital are $376.9 million (Q4 2025), $361.2 million (Q3 2025), and $357.2 million (Q2 2025).